The antimicrobial effect of colistin methanesulfonate on Mycobacterium tuberculosis in vitro

Breda, Shane Vontelin van; Buys, Antoinette V.; Apostolides, Zeno; Nardell, Edward A.; Stoltz, Anton

doi:10.1016/j.tube.2015.05.005

Cited by 18 publications

(18 citation statements)

References 47 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that AS-48 is bactericidal against M. tuberculosis. Several other bacteriocins have been reported as effective against M. tuberculosis in in vitro assays (7,(21)(22)(23): colistin has a MIC of 16 g/ml (24), and nisin showed a MIC of Ͼ60 g/ml against M. tuberculosis H37Ra (7). The authors described variants of nisin with an enhanced antimicrobial activity (22) against M. tuberculosis as well as other naturally occurring bacteriocins such as lacticin 3147 (MIC 90 of 7.5 g/ml) (7).…”

Section: Discussionmentioning

confidence: 99%

Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis

Aguilar-Pérez

Gracia

Rodrigues

et al. 2018

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The increasing incidence of multidrug-resistant strains and the very few drugs available for treatment are promoting the discovery and development of new molecules that could help in the control of this disease. Bacteriocin AS-48 is an antibacterial peptide produced by and is active against several Gram-positive bacteria. We have found that AS-48 was active against , including H37Rv and other reference and clinical strains, and also against some nontuberculous clinical mycobacterial species. The combination of AS-48 with either lysozyme or ethambutol (commonly used in the treatment of drug-susceptible tuberculosis) increased the antituberculosis action of AS-48, showing a synergic interaction. Under these conditions, AS-48 exhibits a MIC close to some MICs of the first-line antituberculosis agents. The inhibitory activity of AS-48 and its synergistic combination with ethambutol were also observed on-infected macrophages. Finally, AS-48 did not show any cytotoxicity against THP-1, MHS, and J774.2 macrophage cell lines at concentrations close to its MIC. In summary, bacteriocin AS-48 has interesting antimycobacterial activity and low cytotoxicity, so further studies will contribute to its development as a potential additional drug for antituberculosis therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis

Aguilar-Pérez

Gracia

Rodrigues

et al. 2018

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…One potentially novel intervention being investigated to reduce infectiousness during end-of-life care is the use of the inhaled antibiotic, dry powder colistin, commonly used for patients with cystic fibrosis. 502 …”

Section: The Lancet Respiratory Medicine Commissionmentioning

confidence: 99%

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

Dheda

Gumbo

Maartens

et al. 2017

The Lancet Respiratory Medicine

506

474

View full text Add to dashboard Cite

“…Little is known about the early bactericidal activity of inhalation of anti-TB drugs. The first report studying the effect of inhalation of colistin on transmission of TB, however, unfortunately not an EBA study, was presented at the Union conference in Vancouver in 2013 [117,118]. Theoretically, inhalation of a drug can produce high concentrations at the site of infection .…”

Section: Five-year Viewmentioning

confidence: 99%

Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers

Alffenaar

Akkerman

Anthony

et al. 2016

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Introduction: Success rates for treatment of extensively drug resistant tuberculosis (XDR-TB) are low due to limited treatment options, delayed diagnosis and inadequate health care infrastructure. Areas covered: This review analyses existing programmes of prevention, diagnosis and treatment of XDR-TB. Improved diagnostic procedures and rapid molecular tests help to select appropriate drugs and dosages. Drugs dosages can be further tailored to the specific conditions of the patient based on quantitative susceptibility testing of the M. tuberculosis isolate and use of therapeutic drug monitoring. Pharmacovigilance is important for preserving activity of the novel drugs bedaquiline and delamanid. Furthermore, biomarkers of treatment response must be developed and validated to guide therapeutic decisions. Expert commentary: Given the currently poor treatment outcomes and the association of XDR-TB with HIV in endemic regions, a more patient oriented approach regarding diagnostics, drug selection and tailoring and treatment evaluation will improve treatment outcome. The different areas of expertise should be covered by a multidisciplinary team and may involve the transition of patients from hospitalized to home or community-based treatment.

show abstract

The antimicrobial effect of colistin methanesulfonate on Mycobacterium tuberculosis in vitro

Cited by 18 publications

References 47 publications

Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis

Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers

Contact Info

Product

Resources

About